153 related articles for article (PubMed ID: 28745127)
1. Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer.
Shahbazi R; Asik E; Kahraman N; Turk M; Ozpolat B; Ulubayram K
Nanomedicine (Lond); 2017 Aug; 12(16):1961-1973. PubMed ID: 28745127
[TBL] [Abstract][Full Text] [Related]
2. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
3. Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
Bircan HA; Gurbuz N; Pataer A; Caner A; Kahraman N; Bayraktar E; Bayraktar R; Erdogan MA; Kabil N; Ozpolat B
Lung Cancer; 2018 Oct; 124():31-39. PubMed ID: 30268477
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
5. Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells.
Mitra M; Kandalam M; Rangasamy J; Shankar B; Maheswari UK; Swaminathan S; Krishnakumar S
Mol Vis; 2013; 19():1029-38. PubMed ID: 23687439
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
7. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.
Tekedereli I; Alpay SN; Tavares CD; Cobanoglu ZE; Kaoud TS; Sahin I; Sood AK; Lopez-Berestein G; Dalby KN; Ozpolat B
PLoS One; 2012; 7(7):e41171. PubMed ID: 22911754
[TBL] [Abstract][Full Text] [Related]
8.
Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
[TBL] [Abstract][Full Text] [Related]
9. Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
Zhao Z; Li Y; Shukla R; Liu H; Jain A; Barve A; Cheng K
Theranostics; 2019; 9(15):4508-4524. PubMed ID: 31285776
[TBL] [Abstract][Full Text] [Related]
10. Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion.
Ashour AA; Gurbuz N; Alpay SN; Abdel-Aziz AA; Mansour AM; Huo L; Ozpolat B
J Cell Mol Med; 2014 Nov; 18(11):2235-51. PubMed ID: 25215932
[TBL] [Abstract][Full Text] [Related]
11. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
Luan X; Rahme K; Cong Z; Wang L; Zou Y; He Y; Yang H; Holmes JD; O'Driscoll CM; Guo J
Eur J Pharm Biopharm; 2019 Apr; 137():56-67. PubMed ID: 30779980
[TBL] [Abstract][Full Text] [Related]
12. What is the impact of eukaryotic elongation factor 2 kinase on cancer: A systematic review.
Li S; Li Y; Bai Y
Eur J Pharmacol; 2019 Aug; 857():172470. PubMed ID: 31226250
[TBL] [Abstract][Full Text] [Related]
13. Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer.
Yang YY; Zhang W; Liu H; Jiang JJ; Wang WJ; Jia ZY
Drug Des Devel Ther; 2021; 15():4961-4972. PubMed ID: 34916779
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells.
Zhang C; Yuan W; Wu Y; Wan X; Gong Y
Life Sci; 2021 Feb; 266():118886. PubMed ID: 33310044
[TBL] [Abstract][Full Text] [Related]
15. Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery.
Song WJ; Du JZ; Sun TM; Zhang PZ; Wang J
Small; 2010 Jan; 6(2):239-46. PubMed ID: 19924738
[TBL] [Abstract][Full Text] [Related]
16. eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis.
Cheng Y; Ren X; Yuan Y; Shan Y; Li L; Chen X; Zhang L; Takahashi Y; Yang JW; Han B; Liao J; Li Y; Harvey H; Ryazanov A; Robertson GP; Wan G; Liu D; Chen AF; Tao Y; Yang JM
Oncogene; 2016 Dec; 35(49):6293-6308. PubMed ID: 27181208
[TBL] [Abstract][Full Text] [Related]
17. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
[TBL] [Abstract][Full Text] [Related]
18. Near-infrared photothermal therapy using EGFR-targeted gold nanoparticles increases autophagic cell death in breast cancer.
Zhang M; Kim HS; Jin T; Moon WK
J Photochem Photobiol B; 2017 May; 170():58-64. PubMed ID: 28390259
[TBL] [Abstract][Full Text] [Related]
19. Captopril-polyethyleneimine conjugate modified gold nanoparticles for co-delivery of drug and gene in anti-angiogenesis breast cancer therapy.
Li M; Li Y; Huang X; Lu X
J Biomater Sci Polym Ed; 2015; 26(13):813-27. PubMed ID: 26166244
[TBL] [Abstract][Full Text] [Related]
20. Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells.
Ashour AA; Abdel-Aziz AA; Mansour AM; Alpay SN; Huo L; Ozpolat B
Apoptosis; 2014 Jan; 19(1):241-58. PubMed ID: 24193916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]